TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib
in two groups of patients:
- Patients with advanced breast cancer that has become worse after taking palbociclib
alone
- Patients with cancers that have an abnormality in a gene called the "retinoblastoma
gene".